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Abstract: Morphine has been shown to affect cell-
mediated and humoral immune parameters. In this
study, we investigated the capacity of in vivo acute
and chronic morphine treatment to modulate in-
terleukin (IL)-10 and IL-12 production by LPS and
interferon--stimulated resident and thioglycol-
late-elicited murine peritoneal macrophages and
the development of tolerance to these effects. One
hour after the acute administration of 5, 10, and
20 mg/Kg morphine, a dose-related decrease of
IL-10 and IL-12 levels was present. The pretreat-
ment with naltrexone at doses up to 20 mg/Kg did
not prevent the decrease of IL-10 and IL-12 in-
duced by morphine. When the drug was adminis-
tered chronically, a differential development of
tolerance to the immune effects was observed. Af-
ter 3 days of treatment, the effect of the acute
challenge with 20 mg/Kg morphine on IL-12 was
lost. In contrast, morphine-induced inhibition of
IL-10 disappeared between 10 and 12 days of
treatment, in parallel with tolerance to the antino-
ciceptive effect. These results suggest that mor-
phine treatment affects macrophage cytokine pro-
duction and that tolerance affects this modulation
differently. J. Leukoc. Biol. 72: 43–48; 2002.
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INTRODUCTION
It is well known that the opiate drug morphine affects natural
and adaptive immunity in the experimental animal as well as in
the human [1]. Acute and chronic morphine administration has
been shown to decrease most T lymphocyte functions, such as
proliferation and cytokine production [2–5], natural killer (NK)
cell activity [2, 6, 7], and macrophage functions including
phagocytosis, tumoricidal activity, and superoxide formation
[3, 8, 9].
Macrophages play a central role in innate and adaptive
immunity. Interleukin (IL)-1, IL-6, and tumor necrosis factor 
(TNF-) produced by macrophages are prominent inflamma-
tory cytokines [10, 11]. Moreover, monocytes/macrophages and
professional antigen presenting cells are the main producers of
IL-12 [12], the critical factor driving the development of T
helper (Th)-1 cells [13], linked to cellular immune responses
and tissue injury.
Conversely, Th2 cells, responsible for humoral responses
and allergy [13], are stimulated by the T lymphocyte cytokine
IL-4 and by IL-10 [13, 14], produced by T lymphocytes as well
as by monocytes/macrophages. Therefore, when considering
the importance of macrophage cytokines in orchestrating the
immune response, we evaluated the effect of morphine in vivo
administration on IL-12 and IL-10 production by murine peri-
toneal macrophages.
Although it is well known that tolerance develops to many of
the effects of morphine, the timing of the development of
tolerance to the immune effects of morphine has been scarcely
taken into consideration. Therefore, we paid particular atten-
tion to the development of tolerance to the effect of morphine




BALB/cJ male mice, 18–20 g body weight (Charles River, Calco, Italy), were
used in the study. Animals were kept on a 12-h light-dark cycle with water and
food ad libitum and were housed six mice to a cage. Each experimental group
consisted of eight animals. Experiments were repeated three times.
Treatment protocols
Mice were inoculated intraperitoneally with 2 ml 3% Brewer’s thioglycollate
medium (Difco, Detroit, MI) for macrophage elicitation. In the acute experi-
ments, morphine hydrochloride (S.A.L.A.R.S., Como, Italy) was injected sub-
cutaneously (s.c.) 4 days after the macrophage elicitation at the doses of 5, 10,
or 20 mg/kg. Control animals were treated with the same volume of saline.
To evaluate the effects of morphine on resident-nonelicited peritoneal
macrophages, some groups of mice were treated acutely only with morphine at
the doses of 10 and 20 mg/Kg or with the same volume of saline. Naltrexone
(S.A.L.A.R.S.) was injected s.c. at the dose of 10 and 20 mg/Kg, alone or 15
min before 20 mg/Kg morphine. In the chronic treatment experiments, 48
animals were used. The same animals were used for antinociceptive and
immune evaluation. Animals underwent the last hot-plate test the day before
being killed for the immune studies. Starting from the thioglycollate injection
day, 24 animals were treated s.c. with morphine twice daily at the doses of 10
mg/Kg for 2 days and 20 mg/Kg for the following days. Control groups (24
animals) received the same volume of saline.
On the day of the hot-plate test, animals received 5 mg/Kg morphine
challenge, supplemented, after the hot-plate test, with a second injection of 15
mg/Kg morphine in order to achieve the maintenance dose of 20 mg/Kg. At the
3rd, 7th, and 12th day of treatment, 16 animals (8 morphine8 saline) were
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killed for evaluation of cytokine production. To evaluate the effects of mor-
phine on resident-nonelicited peritoneal macrophages, two groups of mice, for
a total of 16 animals, were treated chronically with saline or morphine for 7
days according to the same dose schedule described above. In all experiments,
animals received the last morphine injection 1 h before being killed for
macrophage collection.
Harvest of elicited peritoneal macrophages
Peritoneal exudate cells (PEC) were harvested in cold RPMI-1640 medium
(Sigma Chemical Co., St. Louis, MO) plus 10% of fetal calf serum (FCS;
Gibco-BRL, Life Technology, Italy). Viability of cells was checked by the
trypan blue exclusion test. Then PEC from each mouse were resuspended in
RPMI plus 10% FCS at 1  106/ml, and 1 ml aliquots were dispensed into
wells of a 24-well culture plate. Isolation and purification of macrophages were
carried out by adherence to culture plates. After a period of 2 h, nonadherent
cells were removed with the medium, and adherent cells were washed twice
with warm RPMI plus 10% FCS. A differential staining with Diff-Quick (Dade,
Biomap, Italy) and nonspecific esterase staining with -naphthyl acetate
(Sigma Chemical Co.) were used to assess the percentage of macrophages in
the PEC.
Harvest of resident peritoneal macrophages
Peritoneal cells were harvested in cold RPMI plus 10% FCS and were pooled
from four mice per replication. Cells were resuspended in RPMI plus 10% FCS
at 2 106/ml, and 1 ml aliquots were dispensed into wells of a 24-well culture
plate. Nonadherent cells were removed with the medium after an incubation of
2 h, and adherent cells were washed twice with warm RPMI plus 10% FCS.
Cytokine production
Elicited macrophages were primed with 1 g/ml lipopolysaccharides (LPS;
Sigma Chemical Co.) for IL-10 production or with 1 g/ml LPS and 50 U/ml
interferon- (IFN-) (Pharmingen, San Diego, CA) for IL-12 stimulation.
Nonelicited macrophages were stimulated with 1 g/ml LPS for IL-10 produc-
tion or with 10 g/ml LPS and 100 U/ml IFN- for IL-12 evaluation. The
different stimuli were added to the macrophage cultures in a final volume of 1
ml/well RPMI plus 10% FCS, 1% glutamine (Sigma Chemical Co.), 2%
penicillin/streptomycin solution (Sigma Chemical Co.), and 0.1% 2-mercapto-
ethanol (Sigma Chemical Co.; complete medium). The plates were incubated at
37°C and 5% CO2, and supernatants were collected after 24 h in culture and
stored frozen at 80°C for cytokine analysis.
Cytokine enzyme-linked immunosorbent
assay (ELISA)
The levels of IL-12 p70 protein were determined by ELISA protocol as
standardized by Pharmingen. The anti-IL-12 (p35/p70)-capture monoclonal
antibody (mAb; 9 g/ml) was absorbed on a polystyrene 96-well plate, and the
IL-12 present in the sample was bound to the antibody-coated wells. The
biotinylated anti-IL-12 (p40/p70)-detecting mAb (0.25 g/ml) was added to
bind the IL-12 captured by the first antibody. After washing, avidin-peroxidase
(Sigma Chemical Co.) was added to the wells to detect the biotinylated-
detecting antibody, and finally, 2,2-azino-bis (3-ethylbenzthiazoline-6-sul-
fonic acid (Sigma Chemical Co.) substrate was added. A colored product was
formed in proportion to the amount of IL-12 present in the sample that was
measured at an optical density of 405 nm. The amount of cytokine in each
supernatant was extrapolated from the standard curve. The standards were
recombinant cytokine curves generated in doubling dilutions from 30 to 4000
pg/ml.
IL-10 production was measured with the same ELISA protocol except for the
use of anti-IL-10-capture mAb at 2 g/ml, biotinylated anti-IL-10-detecting
mAb at 0.5 g/ml, and a standard curve ranging from 15 to 2000 pg/ml. (All
mAb and recombinant cytokines were from Pharmingen.)
Evaluation of tolerance
The hot-plate test was used to assess nociceptive thresholds. The apparatus
(Basile, Comerio, Italy) was set at a temperature of 54  0.5°C; the cutoff time
was 30 s, chosen to avoid tissue damage to footpads [15]. Time latency was
recorded between the placement of the animal on the hot plate and the moment
at which the mouse licked both the fore paws. To prevent tissue damage and
adaptation, only one hot-plate response was measured per time point. To
evaluate the development of tolerance to the analgesic effect of morphine, the
antinociceptive response was recorded 60 min after challenge with 5 mg/Kg
morphine every other day of chronic treatment. The same animals were used
for antinociceptive and immune evaluation. Animals underwent the last hot-
plate test the day before being killed for the immune studies. The results are
expressed as percentage of the maximal possible effect (% MPE): MPE 	
[(TLBL)/(MLBL)]  100, where BL is the mean basal latency, TL is the
test latency measured after treatments, and ML is the maximal latency ac-
cepted (30 s).
Statistical analysis
Significant differences between groups were assessed by one-way analysis of
variance (ANOVA), followed by Bonferroni’s t-test for multiple comparisons. %
MPE was evaluated by the Kruskall Wallis ANOVA for nonparametric data.
RESULTS
Acute experiments
One hour after the acute administration of 5, 10, and 20 mg/kg
morphine, elicited or resident peritoneal macrophages were
incubated for 24 h in the presence of stimuli for the production
of cytokines. Unstimulated macrophages did not produce de-
tectable levels of IL-12 or IL-10. Activation of cells with LPS
and IFN- induced the production of IL-12 and with LPS of
IL-10.
As demonstrated in Figure 1, acute morphine administra-
tion decreased the production of IL-12 (upper panel) and IL-10
(lower panel) by thioglycollate-elicited macrophages. The ef-
fect on IL-12 started to be present at 10 mg/Kg morphine, but
reached statistical significance only with 20 mg/Kg opiate
drug. Also, IL-10 was significantly reduced only by the highest
dose of morphine.
Although the thioglycollate-elicited macrophages are com-
monly used for cytokine evaluation studies, the possibility
exists that a thioglycollate-mediated activation could interfere
with the results obtained. To rule out this case, we evaluated
the ability of acute morphine administration to alter cytokine
production also by resident nonelicited macrophages.
As shown in Table 1, the levels of IL-12 produced by
resident macrophages after in vitro stimulation with LPS (10
g) plus IFN- (100 units) were extremely low. However, the
acute administration of 20 mg/kg morphine was able to de-
crease the release of lL-12 significantly. It has to be pointed
out, however, that in macrophage cultures derived by mor-
phine-treated mice, the levels of IL-12 were reduced to hardly
detectable levels in our ELISA assays. Basal levels of IL-10
were comparable in thioglycollate-elicited and resident mac-
rophages (Table 1). Also in this case, acute morphine treatment
significantly decreased IL-10 production.
To rule out a toxic effect of morphine on macrophages, 1 h
after morphine administration, the viability of PEC was
checked by the test of trypan blue exclusion. The number of
viable PEC was not affected by morphine:saline: 6.13  1.8 
106 (meanSD) PEC/mouse; morphine, 20 mg/Kg: 6.83 
1.7  106 PEC/mouse. Moreover, we evaluated by morpholog-
ical criteria (Diff-Quick staining) and by nonspecific esterase
44 Journal of Leukocyte Biology Volume 72, July 2002 http://www.jleukbio.org
staining that the percentage of adherent macrophages was not
altered in the different treatment groups (unpublished results).
Effect of naltrexone pretreatment
Figure 2 shows the effects of the acute administration of 10
and 20 mg/Kg naltrexone alone or in combination with 20 mg
mg/Kg morphine on IL-12 (upper panel) and IL-10 (lower
panel) production. Both doses of the opiate antagonist by
themselves were able to induce a slight although significant
decrease of IL-12 and IL-10 production by elicited peritoneal
macrophages. When the antagonist doses were administered 15
min before 20 mg/Kg morphine, IL-12 remained significantly
lower than the one in saline-treated animals. As for IL-10, at
the high dose of 20 mg/Kg, naltrexone seems to partially
prevent the morphine-induced IL-10 reduction.
Chronic experiments
To study the development of tolerance to the antinociceptive
and immunosuppressive effects of morphine, animals were
treated for 12 days with morphine. The animals treated chron-
ically did not seem to suffer from morphine treatment, as shown
by the observation that no body weight difference was observed
between saline- and morphine-treated animals at any of the
treatment days (body weight at the 12th day of treatment:
saline, 23.80.6 grams; morphine, 24.71 grams; meanSD).
Moreover, when we counted the number of PEC at the last day
of morphine treatment (12th day), no significant difference was
Fig. 1. Effect of the acute administration of three doses of morphine on IL-12
(upper panel) and IL-10 (lower panel) production by thioglycollate-elicited
murine peritoneal macrophages. One hour after morphine administration,
macrophages were stimulated in vitro for 24 h in the presence of LPS (IL-10)
or LPS  IFN- (IL-12). Values are means  SD of eight animals (one
experimental session). The experiments were repeated three times with similar
results. *, P 
 0.01 versus saline-treated animals (0).
TABLE 1. IL-12 and IL-10 Production by Resident Macrophages
Obtained from Saline- and Morphine Acutely Treated Mice
IL-12 (pg/mL)
(10 g LPS100 U IFN-)
IL-10 (pg/mL)
(1 g LPS)
Saline 30.2  8a 299  15
Morphine 10 mg/Kg 21.8  6 266  15
Morphine 20 mg/Kg 15.0  6.2* 216  25*
a Values are mean  SD of eight replications. Each replication consisted of
a pool of four mice. * P  0.05 versus saline-treated animals.
Fig. 2. Effect of the pretreatment with naltrexone (10 and 20 mg/Kg) on
morphine (20 mg/Kg) induced decrease of IL-12 and IL-10 production by
elicited macrophages. One hour after morphine administration, macrophages
were stimulated in vitro for 24 h in the presence of LPS (IL-10) or LPS 
IFN- (IL-12). Values are means  SD of eight animals. mor  nalt, Mor-
phine  naltrexone. *, P 
 0.01 versus saline-treated animals. #, P 
 0.05
versus morphine-treated animals.
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observed in comparison with saline-treated animals: saline,
3.3  1.9  106 (meanSD) PEC/mouse; chronic morphine,
3.5  2.3  106 PEC/mouse.
Figure 3 illustrates the development of tolerance to the
antinociceptive of morphine. Each point represents the mean
response of eight mice that were killed the following day for
immune evaluation. Tolerance started by day 6 of treatment
and was complete at the 11th day of chronic morphine admin-
istration. In fact, at this time the acute challenge with 5 mg/kg
morphine did not elicit any significant antinociceptive effect in
comparison to saline-treated animals. The effects of chronic
morphine on cytokine production are shown in Figure 4. As
reported in the upper panel, tolerance developed very rapidly
to the suppressive effect of morphine on IL-12, as it appeared
between the 1st and 3rd day of treatment; indeed, after 3 days
of treatment, no reduction of this cytokine was present after 20
mg/kg morphine. In contrast, the effect of the opiate on IL-10
decrease persisted longer, as it disappeared between the 7th
and the 12th day, in parallel with the development of tolerance
to the antinociceptive effect. Similar results were obtained also
when resident-nonelicited macrophages were used (Table 2).
After 7 days of chronic morphine treatment, tolerance already
developed to the effect of the drug on IL-12 production, and
morphine was still able to decrease IL-10 release.
DISCUSSION
In this study, we demonstrate that the acute administration of
morphine decreased IL-12 and IL-10 production significantly
by LPS and IFN--stimulated murine peritoneal macrophages.
IL-12, a heterodimeric cytokine produced mainly by mono-
cytes/macrophages, is a central inducer of cell-mediated im-
munity that promotes the development, proliferation, and func-
tion of Th1 cells [12, 13]. Th1 cells promote the activation and
function of NK cells and of T cell cytotoxicity and produce IL-2
and IFN- [13]. In contrast, IL-10, produced as a result of
activation of Th2 cells, B lymphocytes, and macrophages, is an
endogenous inhibitor of IL-12 and Th1 responses and stimu-
lates Th2 cell population and humoral immunity [13, 14].
Fig. 3. Analgesic responses to acute administration of morphine (5 mg/Kg) in
mice treated chronically with morphine (see Materials and Methods). Noci-
ceptive thresholds were measured using the hot-plate test immediately before
and 60 min after acute morphine treatment. As controls, animals chronically
treated with saline were used. Values are means  SD of eight animals. Each
point represents the mean response of eight mice, which were killed the
following day for immune evaluation. *, P 
 0.05 versus saline-treated
animals. **, P 
 0.001 versus saline-treated animals.
Fig. 4. Development of tolerance to morphine induced decrease of IL-10 and
IL-12 production by elicited peritoneal macrophages. Mice treated chronically
with morphine for the time indicated were challenged with 20 mg/Kg morphine.
One hour after morphine administration, macrophages were stimulated in vitro for
24 h in the presence of LPS (IL-10) or LPS IFN- (IL-12). Day 1 represents the
data obtained from a single, acute injection of 20 mg/Kg morphine. Values are
means  SD of eight animals (one experimental session). The experiments were
repeated three times with similar results. *, P 
 0.01 versus saline-treated animals.
TABLE 2. IL-12 and IL-10 Production by Resident Macrophages
Obtained from Mice Treated Chronically (7 days)
with Saline or Morphine
IL-12 (pg/mL)
(10 g LPS100 U IFN-)
IL-10 (pg/mL)
(1 g LPS)
Saline 44.3  1.9a 273  19
Morphine 38.7  13 179  11*
a Values are mean  SD of four replications. Each replication consisted of
a pool of four mice. * P  0.05 versus saline-treated animals.
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It has been reported that morphine administration can alter
the distribution of cells in immune organs: both a decrease and
an increase of peritoneal macrophage numbers have been
observed after administration of morphine [16–18]. However,
the cytokine alterations that we observed do not seem to be
because of this condition, as, with our protocol treatment, the
number and viability of macrophages in the peritoneal fluid
were not affected by morphine treatments. Moreover, in our
experimental model, we measured the peritoneal macrophages
production of TNF-, which was never modified by morphine
treatment (unpublished results). We can therefore suggest that
morphine seems to affect specifically the level of IL-10 and
IL-12 rather than alter the composition of peritoneal cells.
Only a few other studies in the literature demonstrate the
effects of morphine administered in vivo on IL-12 and IL-10
production. Peng et al. [19] observed that 48 h after the
implantation of a 75 mg slow-release pellet, IL-12 production
by murine macrophage was indeed increased, and IL-10 was
reduced [18, 19]. The discrepancy with our results showing
IL-12 decrease can be explained easily, however, on the basis
of the different treatment schedules. The peak morphine
plasma concentration reached after the acute injection of 20
mg/kg morphine cannot be compared with the concentrations
reached by the slow release of morphine from the pellet.
Moreover, the authors suggest that the IL-12 increase they
observe could be a result of occult sepsis caused by the 48 h
morphine treatment [20, 21]. Our model is indeed very acute,
as animals are killed only 1 h after morphine administration;
therefore, the possibility of the presence of an underlying
sepsis at this time was unlikely. Moreover, in chronically
treated animals, we did not observe any bacterial growth (un-
published results). Different morphine dosage and route of
administration can be responsible for these different results.
The question of the development of tolerance to the immuno-
logical effects of morphine is still an open one. A certain degree
of tolerance has been shown to develop to some, though not all,
immune effects of morphine. West et al. [22, 23], using a model
with morphine delivered in drinking water, showed that tolerance
develops to the suppression of NK activity in parallel to tolerance
to antinociception, whereas the lymphoproliferation suppression
does not seem to go into tolerance. Similar results were reported
also in the Rhesus monkey [24]. In contrast, other authors [25, 26]
with a twice daily injection protocol showed that the suppression
of concanavalin A lymphoproliferation induced by morphine un-
derwent tolerance in 4–8 days, in parallel to antinociceptive
tolerance. Also in a recent paper [27], development of tolerance to
morphine inhibition of lymphoproliferation was shown, while, in
this case, no tolerance to suppression of NK activity was observed
up to the 8th day of chronic morphine treatment. Moreover, a
differential development of tolerance to antinociception and to T
and B lymphoproliferation suppression was described also in a
chronic pellet implantation model [28]. On the whole, it seems
clear that the development of tolerance to morphine effects can
depend on many factors such as the immune parameter evaluated
and the way of drug administration. Our data on the effects of
chronic morphine on macrophage cytokines seem to confirm this
observation. In fact, when the effects of morphine and the pro-
duction of IL-12 disappeared completely after 3 days of morphine
treatment, the reduction of IL-10 was still present. Therefore, it
has to be considered that the final status of the immune responses
can vary with different morphine regimens.
It is difficult to hypothesize how the modifications of mac-
rophage cytokine production induced by acute or chronic mor-
phine can impact on Th1/Th2 balance, especially considering
that a complex regulatory loop exists between Th1 and Th2
cytokines [12–14]. The results of the present study indicate
that in vivo morphine seems to be a potent inhibitor of mac-
rophage activity, suppressing IL-12 and IL-10 secretion. In
theory, these modifications should diminish Th1 and Th2 re-
sponses or, in any case, should not affect one of the T subsets
particularly. Consistently, the data present in the literature
show that morphine affects cellular and humoral immune re-
sponses [3, 29] as well as the production of Th1 cytokines (IL-2
and IFN-) [2, 30] and Th2 cytokines such as IL-4 [31].
In previous work, we demonstrated that the endogenous opioid
system can find a role in skewing the Th1/Th2 balance toward a
Th2 predominant response [5]. Conversely, it is not surprising that
endogenous opioids could exert a fine modulation on Th1/Th2
responses that is different from the one achieved by injection of
high pharmacological doses of morphine. Recently, it was reported
that morphine administration in vitro can direct T cells toward
Th2 differentiation [32]. This effect was probably mediated by a
direct effect of morphine on T cells.
The differential development of tolerance to immune effects of
morphine can be relevant when considering the chronic morphine
treatment of patients. The final effect of morphine on immune
function can, in fact, vary over time, depending on the balance of
the effects still present at different moments. The effects induced
by the administration of the opioid antagonist naltrexone on IL-12
and IL-10 production are surprising. Indeed, the antagonist seems
to possess some agonistic activity, as it slightly decreases the
cytokine levels, similar to the effects exerted by morphine. More-
over, the pretreatment with the antagonist does not block the
morphine-induced decrease of IL-12 and only at the high dose of
20 mg/Kg seems to block IL-10 reduction slightly. However, we
are aware that this dose is a very high one, and any specificity at
the  opioid receptor should be lost. Two possible scenarios can
explain these results.
The most obvious is that the effects induced by morphine are
not mediated by a classical opioid receptor. In the literature,
most, but not all, of the immune effects of morphine have been
shown to be blocked by the antagonists and therefore mediated
by the  opioid receptors [3, 33]. However, several papers have
described the existence of nonclassical opioid binding sites on
different cell populations that can mediate the non-naloxone-
reversible effects of morphine [3, 33, 34]. Another explanation
could be that under our experimental conditions, naltrexone
could behave as an agonist. Conditions where the opioid an-
tagonists naloxone and naltrexone behave as agonists have
been described already for the main opioid effect, i.e., centrally
and peripherally mediated analgesia [35–39]. Further studies
are needed to better understand the effects of naltrexone.
CONCLUSION
In conclusion, we show that morphine treatment impairs pro-
duction of cytokines by macrophage and that a different pattern
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of modifications can be observed after acute or chronic treat-
ments. Considering the importance of macrophage cytokines on
modulating immune responses, it can be suggested that some of
the effects of morphine on T- and B-cell function can be
ascribed, at least in part, to the effect of the drug on macro-
phages.
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